High quality MT-2 (Melanotan 2 Acetate) 99% purity 5mg/10mg/vial, 10vial/kit Jack
5 Inquiries
6233-83-6
Pharmaceutical
99%
Hong Kong
HUATAI
10vial
2026-11-05
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionWhite SolidBasic Info
-
Product Name:
Oxytocin acetate
Other Name:Oxytocin Identification (15 mg) (COLD SHIPMENT REQUIRED);Orasthin Acetate;Oxytocin Monoacetate;Perlacton Acetate;Pitocin Acetate;Synpitan Acetate;Syntocinon Acetate;Uteracon Acetate
CAS No.:6233-83-6
Molecular Formula:C45H70N12O14S2
InChIKeys:DSZOEVVLZMNAEH-SIVBSZNNNA-N
Molecular Weight:1067.25
EC Number:228-347-5
Color/Form:White to off-white
HScode:2937190000
Categories:
Characteristics-
Critical Temperature & Pressure:
Store at -20°C
Research-
Class:
Synthetic cyclic heptapeptide / non-selective melanocortin receptor agonist
Status:Research compound — NOT FDA approved. FDA issued warning letters. WADA banned substance.
Mechanism:A synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) analog of α-MSH. Melanotan II is a high-affinity non-selective agonist at MC1R, MC3R, MC4R, and MC5R. MC1R activation induces melanogenesis (skin darkening/tanning); MC4R activation affects sexual function, appetite suppression, and energy homeostasis. Carries significant safety risks including nausea, hypertension, and priapism.
EC50 (Human Mc1r Ki):1.2 nM
EC50 (Human Mc5r Ki):1.0 nM
EC50 (Human Mc3r Ki):1.1 nM
EC50 (Human Mc4r Ki):2.1 nM
Source:Wikberg JES, et al. Pharmacol Res. 2000;42(5):393–420. PubChem CID 92432.DOI
Clinical Development:
References-
ChEMBL:
CHEMBL363210
PubChem:Literature:FDA Warning Letters: Melanotan II (unapproved drug); WADA Prohibited List: Melanotan II (S2 hormone modulator)
Disclaimer:Melanotan II is NOT FDA-approved. The FDA has issued multiple warning letters to companies illegally selling Melanotan II as an unapproved new drug. It is also listed on the WADA Prohibited List as a banned substance in sport. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Reproductive toxicity, Category 1A
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 4
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H302 Harmful if swallowed
H360 May damage fertility or the unborn child
H413 May cause long lasting harmful effects to aquatic life
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P273 Avoid release to the environment.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Oxytocin Acetate
10 G Feb 5, 2025 
Brunei
Oxytocin acetate
1 G Apr 23, 2026 
Mexico
Oxytocin acetate
15 MG Aug 4, 2026
Mexico
Oxytocin acetate
5 MT Aug 4, 2026
United States
Oxytocin acetate
30 MG Sep 15, 2025 Post an enquiry for this product